Kazia Therapeutics Announces Phase Ii/Iii Clinical Trial Results For Paxalisib In Glioblastoma; Company Says GBM AGILE Trial Data Shows Clinical Improvement In Prespecified Secondary Analysis
kazia therapeutics宣佈Paxalisib在腦膠質母細胞瘤的II/III期臨床試驗結果;公司表示GBm AGILE試驗數據顯示在預定的次要分析中有臨床改善。